Nav: Home

VIB presents its annual results at BIO2004 in San Francisco

June 03, 2004

San Francisco, BIO2004; The North American biotech convention 'BIO' has blossomed into the place to be. Every year, the international biotech community gathers together at this mega-happening, which this year boasts 20,000 participants. VIB (the Flanders Interuniversity Institute for Biotechnology) is coordinating the Belgian delegation to 'BIO 2004' in San Francisco, where it will present its newly published annual results. These latest results from 2003 - with the large number of major research breakthroughs, 30 patent applications, and almost 50 agreements with industry - clearly position VIB among the top in the world.

In 2003, VIB scientists achieved 180 significant breakthroughs in a variety of domains such as cancer, Alzheimer's disease, inflammatory diseases, human genetics, and plant growth. This figure surpasses that of the previous year, which was already three times as many as at the start of the institute in 1995. This result vaults Flanders' biotechnological research to the top internationally. Also in 2003, VIB expanded its research groups with 3 new ones active in emerging fields in the life sciences. In fact, this is an instance of reverse brain drain, because, after an international search, 3 Belgians proved to be the best candidates and they were eager to return to Flanders after successful careers abroad.

VIB's innovative knowledge is a continuous source of new technologies and inventions that can form the basis for new social and industrial applications, including medical diagnostics and medicines. To bring these applications into being, VIB protects its findings via patents: in 2003, 30 discoveries were sufficiently new and inventive to warrant patent applications. At the same time, VIB entered into nearly 50 collaborative agreements with business and industry. In addition, VIB was the catalyst for the creation of a new network - called 'FlandersBio' - that unites the Flemish biotech industry.
-end-
Along with VIB, 9 Flemish biotech companies will present their breakthroughs and expertise at BIO2004 in San Francisco. They are part of the Belgian delegation that includes over 70 participants. The 9 Flemish companies are: Algonomics; CropDesign; De Clercq, Brants & Partners; Innogenetics; Msource Medical Developments; Perseus; Tigenix; Thromb-X; and Xcellentis. (The attachment provides a brief description of these participating companies.)

On the VIB website (http://www.vib.be/VIB/EN/Downloads/Annual+report/) you can find our new Annual Report. This will provide you with an overview of our research and other activities in 2003.

VIB (the Flanders Institute for Biotechnology)

Related Biotechnology Articles:

The end of biotechnology as we know it
More than 400 attendees from five continents discussed trends and improvements in biotechnology at the European Summit of Industrial Biotechnology (ESIB) in Graz/Austria and talked many topics like a dehumanized research process.
Biotechnology: A growing field in the developing world
A detailed new report surveys a broad cross-section of biotechnology work across developing countries, revealing steady growth in fields tied to human well-being worldwide.
China releases first report on biotechnology in developing countries
The first report on biotechnology in developing countries revealing an overall picture of their biotechnology growth and competitiveness was released on Nov.
Exclusive: Biotechnology leaders surveyed about impact of Trump presidency
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by Genetic Engineering & Biotechnology News showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a 'brain drain' as foreign-born researchers educated in American universities will be more likely to leave.
Novel 'repair system' discovered in algae may yield new tools for biotechnology
The algae C. reinhardtii uses a novel system for releasing an interrupting sequence from a protein -- a technique that may be useful for protein purification.
ESIB -- European Summit of Industrial Biotechnology 2016
'Design' will be the guiding thread of the 2½ days ESIB 2016 which will cover trends in biotech science and industry, cascade design and metabolic engineering, designing nature (e.g. proteins for competitive bioprocesses), in-silico approaches in modern industrial biotechnology, networking opportunities and much more.
Werner Siemens Foundation fosters synthetic biotechnology
With its donation of 11.5 million euro, the Werner Siemens Foundation has facilitated the launch of the teaching and research domain Synthetic Biotechnology at the Technical University of Munich (TUM).
Sanyal Biotechnology LLC announces strategic partnership with OWL Metabolomics, S.L.
Sanyal Biotechnology LLC and One Way Liver S.L. (OWL Metabolomics) have initiated a strategic partnership to provide increased value and additional R&D services to basic research and the pharmaceutical industry, announced at the International Liver Congress in Barcelona, Spain.
ASU researcher improves crop performance with new biotechnology
Researchers with Arizona State University's School of Life Sciences have discovered a way to enhance a plant's tolerance to stress, which in turn improves how it uses water and nutrients from the soil.
New biotechnology to inhibit microRNA activity and novel applications
Today at the 45th Annual Meeting & Exhibition of the American Association for Dental Research, researcher Brad Amendt, University of Iowa, Iowa City, USA, will present a study titled 'New Biotechnology to Inhibit MicroRNA Activity and Novel Applications for Craniofacial and Dental Research.'

Related Biotechnology Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".